VolitionRx Launches €6.3M DETECSEPS Project for Early Sepsis Detection

VolitionRx Limited (NYSE American: VNRX) has announced the launch of the DETECSEPS project, a major initiative aimed at early detection of sepsis. The project is part of the DETECSEPS Consortium, which has secured €6.3 million (approximately $7.3 million) in funding from the French government. The consortium is led by IHU SEPSIS, coordinated by Assistance Publique – Hôpitaux de Paris, and includes partners Hospices Civils de Lyon, IDS France, and Volition. Volition will contribute its proprietary Nu.Q NETs biomarker, specifically the H3.1 blood biomarker, while IDS France will supply an automated analyzer to measure it. The DETECSEPS project will evaluate an innovative approach that combines a routinely used clinical score with Volition’s Nu.Q NETs H3.1 biomarker to assess the risk of patients with suspected infections progressing to sepsis, thereby guiding care during the critical first 24 hours. According to Volition, H3.1 levels can be measured using the IDS France analyzer with results available within one hour. With an estimated 166 million sepsis cases annually worldwide, the company believes this represents a multibillion-dollar total addressable market.

Volition is a multi-national epigenetics company dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and disease monitoring. Its subsidiaries develop and commercialize simple, cost-effective blood tests for various conditions, including some cancers and diseases associated with NETosis, such as sepsis. The company’s R&D activities are based in Belgium, with an innovation lab and office in the U.S. and an office in London. The press release was distributed by MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.